Bellevue Group AG
- SEC CIK
- 0001674546
- Latest filing
- Aug 14, 2026
NBIX holding history
Neurocrine Biosciences Inc in every 13F filed by Bellevue Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NBIX overviewAll 13F holders of NBIXFull Q2 2026 holdings
- Shares (Q2 2026)
- 24,037
- Value
- $4.05M
- % of portfolio
- 0.1%
- Quarters held
- 22
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 24,037 | $4.05M | 0.1% | +19,391+417.4% | Added | Holders |
| Q1 2026 | 4,646 | $612.1K | <0.1% | −1,698,658−99.7% | Reduced | Holders |
| Q4 2025 | 1,703,304 | $241.6M | 4.6% | −59,801−3.4% | Reduced | Holders |
| Q3 2025 | 1,763,105 | $247.5M | 5.1% | −56,895−3.1% | Reduced | Holders |
| Q2 2025 | 1,820,000 | $228.8M | 5.0% | 00.0% | Unchanged | Holders |
| Q1 2025 | 1,820,000 | $201.3M | 4.5% | 00.0% | Unchanged | Holders |
| Q4 2024 | 1,820,000 | $248.4M | 4.8% | −43,800−2.4% | Reduced | Holders |
| Q3 2024 | 1,863,800 | $214.7M | 3.5% | −34,840−1.8% | Reduced | Holders |
| Q2 2024 | 1,898,640 | $261.4M | 4.2% | −157,234−7.6% | Reduced | Holders |
| Q1 2024 | 2,055,874 | $283.5M | 4.3% | −374,626−15.4% | Reduced | Holders |
| Q4 2023 | 2,430,500 | $320.2M | 4.9% | −153,050−5.9% | Reduced | Holders |
| Q3 2023 | 2,583,550 | $290.6M | 4.7% | −29,250−1.1% | Reduced | Holders |
| Q2 2023 | 2,612,800 | $246.4M | 3.5% | −5000.0% | Reduced | Holders |
| Q1 2023 | 2,613,300 | $264.5M | 3.8% | −159,994−5.8% | Reduced | Holders |
| Q4 2022 | 2,773,294 | $331.2M | 4.4% | −81,852−2.9% | Reduced | Holders |
| Q3 2022 | 2,855,146 | $303.2M | 4.4% | +10,841+0.4% | Added | Holders |
| Q2 2022 | 2,844,305 | $277.3M | 3.9% | −179,146−5.9% | Reduced | Holders |
| Q1 2022 | 3,023,451 | $283.4M | 3.3% | −157,100−4.9% | Reduced | Holders |
| Q4 2021 | 3,180,551 | $270.9M | 2.8% | +176,500+5.9% | Added | Holders |
| Q3 2021 | 3,004,051 | $288.1M | 2.9% | −13,700−0.5% | Reduced | Holders |
| Q2 2021 | 3,017,751 | $293.7M | 2.9% | −256,800−7.8% | Reduced | Holders |
| Q1 2021 | 3,274,551 | $318.4M | 3.4% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.